AI uncovers BRP, a natural appetite-suppressing molecule that rivals Ozempic in animals
Stanford researchers used AI to find BRP, a natural molecule that cut food intake by up to 50% in animals by targeting the hypothalamus, not the gut.
Summary
Obesity drugs like semaglutide (Ozempic) work, but they act on receptors in the brain, gut, and pancreas, which helps explain side effects such as nausea, constipation, and muscle loss. Stanford Medicine researchers used artificial intelligence to sift through thousands of small protein fragments and identified a naturally occurring molecule called BRP. In animal experiments, BRP cut food intake by up to 50% and promoted fat loss. It appears to act specifically on the hypothalamus, the brain region that controls hunger and metabolism, and it activates different brain cells than GLP-1 drugs do. That selectivity could mean fewer digestive problems and less muscle loss. The work was published in Nature, and the senior author has cofounded a company to move BRP toward human trials. The results are promising but remain preclinical: safety and effectiveness in people are still unknown.
Detailed Summary
Obesity is one of the biggest drivers of age-related disease, including type 2 diabetes, heart disease, and loss of physical function. GLP-1 drugs such as semaglutide (Ozempic) have transformed treatment, yet they come with trade-offs. Their receptors sit in the brain, gut, pancreas, and other tissues, so the drugs slow digestion, lower blood sugar, and often cause nausea, constipation, and loss of lean mass. A more targeted option would be a meaningful advance.
Stanford Medicine scientists, led by Laetitia Coassolo with senior author Katrin Svensson, used artificial intelligence to search through the many small protein fragments the body produces, most of which have no important biological role. This approach surfaced BRP, a naturally occurring molecule. In animal experiments, BRP reduced food intake by up to 50% and promoted fat loss, effects comparable to semaglutide. The findings were published in Nature.
The key insight is where BRP acts. Rather than affecting multiple organs, it appears to work specifically in the hypothalamus, the deep brain region that regulates hunger, energy use, and metabolism. Although it influences some of the same broad metabolic functions as semaglutide, it activates different populations of brain cells. That distinction suggests appetite could be controlled more precisely, with fewer digestive side effects and less muscle loss.
The practical implications are still some way off. Svensson has cofounded a company to advance BRP toward human clinical trials, and the team is preparing to test whether it is safe and effective in people. For now, nothing here changes clinical practice or personal strategy. If BRP works in humans, it could eventually give clinicians a tool that lowers body fat while better preserving muscle, which matters for healthspan and mobility in older adults.
Caveats are significant. The data come from animals, and many promising metabolic compounds fail in human trials. Claims about avoiding nausea, constipation, and muscle loss are so far hopeful projections rather than demonstrated outcomes. Long-term safety, dosing, delivery, and cost are unknown, and a commercial interest exists. Readers should look to the Nature paper and future trial results.
Key Findings
- AI screening of small protein fragments identified BRP, a naturally occurring molecule that suppresses appetite.
- BRP cut food intake by up to 50% and promoted fat loss in animal experiments.
- BRP appears to act in the hypothalamus, unlike semaglutide, whose receptors also sit in the gut and pancreas.
- BRP activates different brain cell populations than GLP-1 drugs, which may mean fewer digestive side effects and less muscle loss.
- Human safety and efficacy are untested; a company cofounded by the senior author is pursuing clinical trials.
Methodology
This is a university-sourced news report on a preclinical study published in Nature, summarized via ScienceDaily from Stanford Medicine. The evidence comes from animal experiments combined with AI-driven molecule discovery. The excerpt is truncated, so details of the methods and models are limited.
Study Limitations
Findings are from animals, and the claims about fewer side effects and muscle preservation are not yet shown in humans. The article is partly truncated and gives few quantitative details on comparisons with semaglutide, dosing, or duration. The senior author has a commercial stake, so verify results in the original Nature paper and future clinical trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: